Cargando…

Blocking autophagy overcomes resistance to dual histone deacetylase and proteasome inhibition in gynecologic cancer

Histone deacetylase (HDAC) inhibitors and proteasome inhibitors have been approved by the FDA for the treatment of multiple myeloma and lymphoma, respectively, but have not achieved similar activity as single agents in solid tumors. Preclinical studies have demonstrated the activity of the combinati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bi, Jianling, Zhang, Yuping, Malmrose, Paige K., Losh, Haley A., Newtson, Andreea M., Devor, Eric J., Thiel, Kristina W., Leslie, Kimberly K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763941/ https://www.ncbi.nlm.nih.gov/pubmed/35039480 http://dx.doi.org/10.1038/s41419-022-04508-2

Ejemplares similares

Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations
por: Meng, Xiangbing, et al.
Publicado: (2018)

Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing
por: Bi, Jianling, et al.
Publicado: (2021)

Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy
por: Bi, Jianling, et al.
Publicado: (2021)

Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
por: Chhabra, Saurabh
Publicado: (2017)

Bacterial, Archaea, and Viral Transcripts (BAVT) Expression in Gynecological Cancers and Correlation with Regulatory Regions of the Genome
por: Gonzalez-Bosquet, Jesus, et al.
Publicado: (2021)

The Dawning of the Age of Personalized Medicine in Gynecologic Oncology
por: Leslie, Kimberly K., et al.
Publicado: (2020)

Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer
por: McDonald, Megan E., et al.
Publicado: (2019)

Creation and validation of models to predict response to primary treatment in serous ovarian cancer
por: Gonzalez Bosquet, Jesus, et al.
Publicado: (2021)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Population Substructure Has Implications in Validating Next-Generation Cancer Genomics Studies with TCGA
por: Miller, Marina D., et al.
Publicado: (2019)

Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma
por: Yeon, Minjeong, et al.
Publicado: (2020)

Prediction of chemo-response in serous ovarian cancer
por: Gonzalez Bosquet, Jesus, et al.
Publicado: (2016)

Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior
por: Reyes, Henry D., et al.
Publicado: (2019)

Oncomorphic TP53 Mutations in Gynecologic Cancers Lose the Normal Protein:Protein Interactions with the microRNA Microprocessing Complex
por: Brachova, Pavla, et al.
Publicado: (2014)

Synthetic Lethal Drug Combinations Targeting Proteasome and Histone Deacetylase Inhibitors in TP53-Mutated Cancers
por: Das, Shaoli, et al.
Publicado: (2020)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

An integrated prediction model of recurrence in endometrial endometrioid cancers
por: Miller, Marina D, et al.
Publicado: (2019)

p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers
por: Devor, Eric J., et al.
Publicado: (2017)

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)

Identification of Novel Fusion Transcripts in High Grade Serous Ovarian Cancer
por: Newtson, Andreea, et al.
Publicado: (2021)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Proteasome Inhibitors Silence Oncogenes in Multiple Myeloma through Localized Histone Deacetylase 3 Stabilization and Chromatin Condensation
por: Maneix, Laure, et al.
Publicado: (2022)

Targeting histone deacetylases for the treatment of disease
por: Lawless, M W, et al.
Publicado: (2009)

Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

A Prediction Model for Preoperative Risk Assessment in Endometrial Cancer Utilizing Clinical and Molecular Variables
por: Salinas, Erin A., et al.
Publicado: (2019)

Regulation of Osteoclast Differentiation and Skeletal Maintenance by Histone Deacetylases
por: Faulkner, Bora, et al.
Publicado: (2019)

Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)
por: Lu, Guang, et al.
Publicado: (2023)

Microbial Communities in Gynecological Cancers and Their Association with Tumor Somatic Variation
por: Gonzalez-Bosquet, Jesus, et al.
Publicado: (2023)

Chemical Phylogenetics of Histone Deacetylases
por: Bradner, James E., et al.
Publicado: (2010)

Histone deacetylases in viral infections
por: Herbein, Georges, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone deacetylase signaling in cardioprotection
por: Lehmann, Lorenz H., et al.
Publicado: (2013)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton
por: Mithraprabhu, S, et al.
Publicado: (2014)

ATM inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest
por: Scotto, Luigi, et al.
Publicado: (2020)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Attenuation of Choroidal Neovascularization by Histone Deacetylase Inhibitor
por: Chan, Nymph, et al.
Publicado: (2015)

Selective inhibition of histone deacetylase 2 induces p53-dependent survivin downregulation through MDM2 proteasomal degradation
por: Seo, Sung-Keum, et al.
Publicado: (2014)

Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
por: Huang, Ying, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ekjfosfms6pr5alf6jor1t59fm